Ultragenyx Pharmaceutical Accounts Payable

Ultragenyx Pharmaceutical (RARE) currently reports a accounts payable of $39M as of June 2026. That compares with $34M in the prior-year period — up 13.9% year over year. Use the charts on this page to explore Ultragenyx Pharmaceutical's accounts payable history and peer comparisons.

Ultragenyx Pharmaceutical's accounts payable increased from $34M to $39M — a 13.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ultragenyx Pharmaceutical reported $39M in accounts payable as of June 2026. That compares with $34M in the prior-year period — up 13.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $39M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ultragenyx Pharmaceutical, and consider following RARE for alerts when major investors trade the stock.

Ultragenyx Pharmaceutical is classified in the Healthcare sector. On accounts payable, it currently shows $39M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RARE with unrelated industries.